Skip to main content
. 2009 Nov 19;298(2):G267–G274. doi: 10.1152/ajpgi.00435.2009

Fig. 6.

Fig. 6.

Effect of motor protein inhibitors on hSVCT2 trafficking. A: stable hSVCT2-YFP expressing HepG2 cells were treated with DMSO (control), a cytoplasmic dynein inhibitor (vanadate, 100 μM, 24 h), a kinesin inhibitor (monastrol, 100 μM, 24 h), myosin inhibitors (BDM, 20 mM, 24 h) or blebbistatin (100 μM, 24 h). B: uptake of [14C]ascorbic acid in drug-treated stable hSVCT2-YFP expressing HepG2 cells. C: flow cytometry analysis of the mean fluorescence intensity of populations of hSVCT2-YFP expressing HepG2 cells treated with indicated motor protein inhibitors. Values are means ± SE. (*P < 0.01).